Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.

Yu MiuraAtsuto MouriKyoichi Kaira Ou YamaguchiAyako ShionoKosuke HashimotoFuyumi NishiharaShun ShinomiyaTomoe AkagamiYoshitake MurayamaTakanori AbeShin-Ei NodaShingo KatoKunihiko KobayashiHiroshi Kagamu

Published in: Thoracic cancer (2020)

The adherence to lung dose constraints such as V20 as well as close treatment monitoring are a prerequisite for the management of pneumonitis during maintenance therapy with durvalumab.

Keyphrases

advanced non small cell lung cancer
locally advanced
epidermal growth factor receptor
rectal cancer
stem cells
type diabetes
squamous cell carcinoma
radiation therapy
rheumatoid arthritis
liver metastases
insulin resistance
replacement therapy
idiopathic pulmonary fibrosis
smoking cessation